APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy (DMD) Therapeutics

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Selected research

Industry Growth & Trends

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Growth and Trends Forecast to 2032

27 December 202588 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

According to APO Research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Duchenne Muscular Dystrophy (DMD) Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021-2026) Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2027-2032) Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends Table 37. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers Table 38. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges Table 39. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints Table 40. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Company Headquarters & Area Served Table 44. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company, Product Type & Application Table 45. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sarepta Therapeutics Company Information Table 49. Sarepta Therapeutics Business Overview Table 50. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 52. Sarepta Therapeutics Recent Development Table 53. PTC Therapeutics Company Information Table 54. PTC Therapeutics Business Overview Table 55. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 57. PTC Therapeutics Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 62. Pfizer Recent Development Table 63. Bristol-Myers Squibb Company Information Table 64. Bristol-Myers Squibb Business Overview Table 65. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 67. Bristol-Myers Squibb Recent Development Table 68. Italfarmaco Company Information Table 69. Italfarmaco Business Overview Table 70. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 72. Italfarmaco Recent Development Table 73. Santhera Pharmaceuticals Company Information Table 74. Santhera Pharmaceuticals Business Overview Table 75. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 77. Santhera Pharmaceuticals Recent Development Table 78. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 79. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 80. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2026) Table 81. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 82. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Country (2027-2032) Table 83. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 85. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2026) Table 86. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Country (2027-2032) Table 88. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 90. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2026) Table 91. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Country (2027-2032) Table 93. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 95. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2026) Table 96. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Country (2027-2032) Table 98. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 100. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2026) Table 101. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Country (2027-2032) Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Image Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021-2032) Figure 7. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Exondys Image Figure 13. Global Exondys Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Emflaza Image Figure 15. Global Emflaza Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Translarna Image Figure 17. Global Translarna Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type 2025 VS 2032 Figure 20. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032) Figure 21. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032) Figure 23. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032) Figure 25. Hospitals Image Figure 26. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Clinics Image Figure 28. Global Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Home Care Image Figure 30. Global Home Care Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application 2025 VS 2032 Figure 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032) Figure 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032) Figure 36. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 43. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 46. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 49. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 52. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2021-2032)
2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Exondys
  3. 2.1.2 Emflaza
  4. 2.1.3 Translarna
  5. 2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  6. 2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions
  10. 2.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospitals
  3. 3.1.2 Clinics
  4. 3.1.3 Home Care
  5. 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  6. 3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions
  10. 3.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
  2. 4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers
  3. 4.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges
  4. 4.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2026)
  2. 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company, Product Type & Application
  5. 5.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Duchenne Muscular Dystrophy (DMD) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sarepta Therapeutics
  2. 6.1.1 Sarepta Therapeutics Company Information
  3. 6.1.2 Sarepta Therapeutics Business Overview
  4. 6.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  6. 6.1.5 Sarepta Therapeutics Recent Developments
  7. 6.2 PTC Therapeutics
  8. 6.2.1 PTC Therapeutics Company Information
  9. 6.2.2 PTC Therapeutics Business Overview
  10. 6.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  12. 6.2.5 PTC Therapeutics Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Italfarmaco
  26. 6.5.1 Italfarmaco Company Information
  27. 6.5.2 Italfarmaco Business Overview
  28. 6.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  30. 6.5.5 Italfarmaco Recent Developments
  31. 6.6 Santhera Pharmaceuticals
  32. 6.6.1 Santhera Pharmaceuticals Company Information
  33. 6.6.2 Santhera Pharmaceuticals Business Overview
  34. 6.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  36. 6.6.5 Santhera Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst